Publication at Faculty of Medicine in Hradec Králové |
2020
Abstract
The clinical value of the assessment of various subsets of especially T cells in peripheral blood of patients with multiple sclerosis treated with fingolimod is discussed. As the body of knowledge in this area is still insufitient, it is premature to exploit these biomarkers in daily clinical practice.
